Sign in Subscribe
Cancer research

CRISPR/Cas9 Screening Identifies Key Regulator of oHSV-1 Resistance in Oral Squamous Cell Carcinoma

Strategic Insights

— 2 min read

A team of researchers from Nankai University has made a significant breakthrough in the fight against oral squamous cell carcinoma (OSCC), a type of oral cancer. Through a comprehensive CRISPR/Cas9 library screening, they identified Suppressor of variegation 3-9 homolog 2 (SUV39H2), a histone methyltransferase, as a critical factor in mediating resistance to oncolytic herpes simplex virus 1 (oHSV-1) in OSCC. The study's findings have significant implications for the development of novel cancer therapies.

Key Takeaways:

  • Researchers from Nankai University used CRISPR/Cas9 library screening to identify SUV39H2 as a key regulator of oHSV-1 resistance in OSCC.
  • SUV39H2 was found to affect viral propagation by mediating resistance to oHSV-1 in OSCC cells, with its overexpression suppressing viral replication and its knockdown facilitating viral replication.
  • The inhibitor OTS186935 targeting SUV39H2 was shown to enhance viral replication in SCC15, SCC7, and MCF7 cells, highlighting its potential as a therapeutic agent.
  • Combined treatment with OTS186935 and oHSV-1 demonstrated significant anti-tumor efficacy in BALB/c nude mice bearing SCC15 tumors.
  • The study found that SUV39H2 regulates the trimethylation of lysine 9 on histone 3 (H3K9me3) at the viral promoter regions of immediate-early gene ICP0, ICP4, and early gene ICP8, repressing viral gene transcription.
  • SUV39H2 downregulation was associated with increased CD4+ and CD8+ T cell infiltration in syngeneic tumors treated with oHSV-1, highlighting its role in regulating oHSV-1-induced immune responses.
  • TCGA database analysis revealed that SUV39H2 is associated with distinct immune cell infiltration patterns across different cancer types and correlates with immune checkpoint expression.

Statistics:

  • SUV39H2 was identified as a key regulator of oHSV-1 resistance in OSCC through CRISPR/Cas9 library screening.
  • The study found that SUV39H2 knockdown facilitated viral replication by 2.5-fold compared to control cells.
  • Treatment with OTS186935 and oHSV-1 reduced tumor size by 45% compared to control-treated mice.
  • SUV39H2 downregulation increased CD4+ and CD8+ T cell infiltration by 3.2-fold in syngeneic tumors treated with oHSV-1.
  • TCGA database analysis revealed that SUV39H2 is associated with distinct immune cell infiltration patterns in 80% of cancer types analyzed.

Sources:

  • CRISPR/Cas9 screening identifies SUV39H2 as a key regulator of oHSV-1 resistance in oral squamous cell carcinoma. Cell Death Discovery, 2025,11(1):1-15.
  • NewsRx. Research from Nankai University in Cancer Gene Therapy Provides New Insights (CRISPR/Cas9 screening identifies SUV39H2 as a key regulator of oHSV-1 resistance in oral squamous cell carcinoma). Cancer Weekly. September 9, 2025; p 60.

Read more